‘Ayurveda is effective and cheaper’

Source: The Hitavada      Date: 19 Oct 2017 09:29:34


 

Business Bureau,

SHRI Baidyanath Ayurved Bhavan Private Limited celebrated ‘Dhanwantari Samaroh’ and awarded four ‘Vaidyas’ from Central India for their contribution to the field of ancient medical science at a function held here recently.


The four doctors who were honoured and given certificates of appreciation included Manoj Chowksey, Medha Joshi, Amol Bhandarkar and Anand Temburnikar. Dr Meera Aurangabadkar, Senior Faculty, Government Ayurvedic College, was in the chair.


Dr Chowksey said, “The general notion that taking Ayurvedic treatment does not suit the budget of a common man is wrong. In fact, from billionaires to those belonging to the poor strata of society are benefited by Ayurveda. Medicines of this branch are cheaper and hence affordable.”


Dr Joshi said, “With advancement in science and technology, research in Ayurveda too needed to be encouraged.”
Dr Bhandarkar said, “Studies conducted by Ayurveda researchers on diseases like sickle cell have shown positive impact in villages. Poor villagers can get treatment at affordable rates and cured of many ailments.”
Dr Temburnikar dedicated the award to his work on skin, yoga and ‘Panchgavya’, besides various experiments he conducted over a period of time.


Suresh Sharma, MD of Baidyanath, said, “Ayurveda is an ocean of knowledge gained by countless ‘Rishis’ thousands of years back which they passed on to the next generations. He said that time has come that the government stopped giving Ayurveda secondary treatment and included it in MBBS curriculum. B K Shrikhande, President of R&D of Baidyanath, said, “Ayurveda has been one of the oldest forms of medicine and is known to treat incurable diseases.”


Bhawana Sharma, CEO of Siddhayu Pharma, said that an integrated platform should be created on which practitioners of different pathies come together and exchange knowledge purely based on scientific and practical approach so that they could pick the best for treatment. Patients will be the ultimate beneficiaries, Sharma said.